Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 7/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 7/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 7/20 | 0.54 |
| ▸ | BRD4 | O60885 | 8/20 | 0.54 |
| ▸ | BRD2 | P25440 | 6/20 | 0.54 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.54 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TAF1 | P21675 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.51 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.51 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26071793 | 1.00 | PDK1 (0.54) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL26071914 | 0.91 | CYP11B1 (0.47) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL14756232 | 0.90 | PDK1 (0.47) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL30366656 | 0.89 | BRD4 (0.53) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL14756761 | 0.86 | PDK1 (0.45) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL14756175 | 0.86 | BRD4 (0.56) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL26072484 | 0.86 | PDK1 (0.48) | PDK1PDK2PDK3PDK4MAPK1 | |
| SCHEMBL30366353 | 0.86 | PDK1 (0.48) | PDK1PDK2PDK3PDK4MAPK1 | |
| SCHEMBL26071772 | 0.85 | ALDH1A1 (0.45) | PDK1PDK2PDK3PDK4BRD4 | |
| SCHEMBL26071929 | 0.85 | ALDH1A1 (0.45) | PDK1PDK2PDK3PDK4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| EP-4165045-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | Monash University (AU) | 2023-04-19 | — | — | EP | disclosed |
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3168213-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | PDK1 540/4885PDK2 783/4885PDK3 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.